On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017

OBJECTIVES: We aimed to calculate cumulative hepatitis C virus (HCV) treatment coverage among individuals enrolled in opioid agonist therapy (OAT) in Norway between 2013 and 2017 and to document the treatment transition to direct-acting antiviral (DAA) agents. Moreover, we aimed to describe adherenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Aas, Christer Frode, Vold, Jørn Henrik, Skurtveit, Svetlana, Odsbu, Ingvild, Chalabianloo, Fatemeh, Økland, Jan Magnus, Leiva, Rafael Alexander Modahl, Vickerman, Peter, Johansson, Kjell Arne, Fadnes, Lars T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451452/
https://www.ncbi.nlm.nih.gov/pubmed/32847908
http://dx.doi.org/10.1136/bmjopen-2019-036355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451452/
https://www.ncbi.nlm.nih.gov/pubmed/32847908
http://dx.doi.org/10.1136/bmjopen-2019-036355

Ejemplares similares